Understanding how antibodies fight influenza viruses
Sequence-function relationship of influenza broadly neutralizing antibodies
This study is looking at how certain antibodies can fight off different types of flu viruses, especially the 1918 H1N1 strain, to help create a better flu vaccine that works for more people, and you might be asked to share samples or information to help with this important research.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-10995304 on NIH RePORTER |
What this research studies
This research investigates the relationship between the structure and function of broadly neutralizing antibodies (bnAbs) that target influenza viruses, particularly the 1918 H1N1 strain. By using advanced high-throughput techniques, the study aims to identify the specific sequences of these antibodies that can effectively neutralize various influenza subtypes. The goal is to contribute to the development of a universal influenza vaccine that can provide broader protection against diverse strains, potentially improving vaccine effectiveness for patients. Participants may be involved in providing samples or data that help elucidate these antibody responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been infected with influenza or those who are at high risk for influenza infections, such as the elderly or immunocompromised.
Not a fit: Patients who have never been exposed to influenza or those with conditions that prevent them from producing antibodies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a universal influenza vaccine, significantly improving protection against seasonal and pandemic influenza.
How similar studies have performed: Previous research has shown promise in developing broadly neutralizing antibodies for other viruses, indicating potential success for similar approaches in influenza vaccine development.
Where this research is happening
Champaign, United States
- University of Illinois at Urbana-Champaign — Champaign, United States (Active)
Researchers
- Principal investigator: Wu, Nicholas C. — University of Illinois at Urbana-Champaign
- Study coordinator: Wu, Nicholas C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.